BCL2 and acute myeloid leukemia: For example, activation of RAS/MAPK signaling through functional [90] or genomic alterations [19,22] is a common mechanism of resistance to inhibitors of FLT3 or the antiapoptotic protein BCL-2, which are currently used in the treatment of AML.